Loading…
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis
Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-...
Saved in:
Published in: | Psychiatry research 2011-05, Vol.187 (1), p.42-48 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703 |
---|---|
cites | cdi_FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703 |
container_end_page | 48 |
container_issue | 1 |
container_start_page | 42 |
container_title | Psychiatry research |
container_volume | 187 |
creator | Stauffer, Virginia L Case, Michael Kinon, Bruce J Conley, Robert Ascher-Svanum, Haya Kollack-Walker, Sara Kane, John McEvoy, Joseph Lieberman, Jeffrey |
description | Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-driven threshold for early response of ≥ 26.2% improvement from baseline on the Positive and Negative Syndrome Scale (PANSS0–6 ) Total score to determine whether response at Week 2 of treatment may predict response at Week 12 in a randomized, double-blind trial of olanzapine versus haloperidol for treatment of patients with first-episode psychosis ( N = 225). Later response was defined as a ≥ 40% and ≥ 50% improvement in PANSS Total0–6 score and as remission. At Week 2, 43% (97/225) of patients were identified as early responders. At a threshold for later response of ≥ 50% improvement in PANSS0–6 Total score, early non-response most strongly predicted later non-response, demonstrating high specificity (74%) and high negative predictive value (80%). As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis. |
doi_str_mv | 10.1016/j.psychres.2010.11.017 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_860188813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165178110007092</els_id><sourcerecordid>860188813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEokvhFSpfEKcsHiexnQsCVeWPVIkDcLa8zkTrbTYOHm9RHoJ3xunuUokLJ1v2b76xv2-K4gr4GjjIt7v1RLPbRqS14MshrDmoJ8UKtBKlAlE9LVYZbEpQGi6KF0Q7zrmAtn1eXAgAqVvBV8XvGxuHmWWdKYyELAVmx-QfxEPyjqUtRjvNzBKzzA1-9M4ObG_jHUYWekaHDeHPA47pUcSPSxlLEW3aLzeZm2zyeUvsl09b1vtIqcTJU-iQHbuRp5fFs94OhK9O62Xx4-PN9-vP5e3XT1-uP9yWrm5EKl0rne21dNK2kotKSnC1VbaqhWvaqpWN1thXVaMs1NyKrulVJzsnhdw0SvHqsnhz1J1iyG-nZPaeHA6DHTEcyGjJQWsNVSblkXQxEEXszRR9_v1sgJslCbMz5yTMkoQBMDmJXHh1anHY7LH7W3a2PgOvT4ClbGkf7eg8PXI1b5v6Qej9kcNsyL3HaMhlJx12PqJLpgv-_29594_EOcg7nJF24RDHbLcBQ8Jw822Zm2VsIE-M4q2o_gCpscJs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>860188813</pqid></control><display><type>article</type><title>Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis</title><source>Elsevier</source><creator>Stauffer, Virginia L ; Case, Michael ; Kinon, Bruce J ; Conley, Robert ; Ascher-Svanum, Haya ; Kollack-Walker, Sara ; Kane, John ; McEvoy, Joseph ; Lieberman, Jeffrey</creator><creatorcontrib>Stauffer, Virginia L ; Case, Michael ; Kinon, Bruce J ; Conley, Robert ; Ascher-Svanum, Haya ; Kollack-Walker, Sara ; Kane, John ; McEvoy, Joseph ; Lieberman, Jeffrey</creatorcontrib><description>Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-driven threshold for early response of ≥ 26.2% improvement from baseline on the Positive and Negative Syndrome Scale (PANSS0–6 ) Total score to determine whether response at Week 2 of treatment may predict response at Week 12 in a randomized, double-blind trial of olanzapine versus haloperidol for treatment of patients with first-episode psychosis ( N = 225). Later response was defined as a ≥ 40% and ≥ 50% improvement in PANSS Total0–6 score and as remission. At Week 2, 43% (97/225) of patients were identified as early responders. At a threshold for later response of ≥ 50% improvement in PANSS0–6 Total score, early non-response most strongly predicted later non-response, demonstrating high specificity (74%) and high negative predictive value (80%). As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis.</description><identifier>ISSN: 0165-1781</identifier><identifier>EISSN: 1872-7123</identifier><identifier>DOI: 10.1016/j.psychres.2010.11.017</identifier><identifier>PMID: 21168920</identifier><identifier>CODEN: PSRSDR</identifier><language>eng</language><publisher>Kidlington: Elsevier Ireland Ltd</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Antipsychotic Agents - therapeutic use ; Basal Ganglia Diseases - chemically induced ; Benzodiazepines - therapeutic use ; Biological and medical sciences ; Double-Blind Method ; Female ; Follow-Up Studies ; Haloperidol ; Haloperidol - therapeutic use ; Humans ; International Cooperation ; Male ; Medical sciences ; Mental Disorders - drug therapy ; Mental Disorders - physiopathology ; Neuropharmacology ; Olanzapine ; Pharmacology. Drug treatments ; Prediction models ; Predictive Value of Tests ; Psychiatric Status Rating Scales ; Psychiatry ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Schizophrenia ; Time Factors ; Treatment Outcome ; Weight Gain - drug effects ; Young Adult</subject><ispartof>Psychiatry research, 2011-05, Vol.187 (1), p.42-48</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2010 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703</citedby><cites>FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24095417$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21168920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stauffer, Virginia L</creatorcontrib><creatorcontrib>Case, Michael</creatorcontrib><creatorcontrib>Kinon, Bruce J</creatorcontrib><creatorcontrib>Conley, Robert</creatorcontrib><creatorcontrib>Ascher-Svanum, Haya</creatorcontrib><creatorcontrib>Kollack-Walker, Sara</creatorcontrib><creatorcontrib>Kane, John</creatorcontrib><creatorcontrib>McEvoy, Joseph</creatorcontrib><creatorcontrib>Lieberman, Jeffrey</creatorcontrib><title>Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis</title><title>Psychiatry research</title><addtitle>Psychiatry Res</addtitle><description>Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-driven threshold for early response of ≥ 26.2% improvement from baseline on the Positive and Negative Syndrome Scale (PANSS0–6 ) Total score to determine whether response at Week 2 of treatment may predict response at Week 12 in a randomized, double-blind trial of olanzapine versus haloperidol for treatment of patients with first-episode psychosis ( N = 225). Later response was defined as a ≥ 40% and ≥ 50% improvement in PANSS Total0–6 score and as remission. At Week 2, 43% (97/225) of patients were identified as early responders. At a threshold for later response of ≥ 50% improvement in PANSS0–6 Total score, early non-response most strongly predicted later non-response, demonstrating high specificity (74%) and high negative predictive value (80%). As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Basal Ganglia Diseases - chemically induced</subject><subject>Benzodiazepines - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Haloperidol</subject><subject>Haloperidol - therapeutic use</subject><subject>Humans</subject><subject>International Cooperation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental Disorders - drug therapy</subject><subject>Mental Disorders - physiopathology</subject><subject>Neuropharmacology</subject><subject>Olanzapine</subject><subject>Pharmacology. Drug treatments</subject><subject>Prediction models</subject><subject>Predictive Value of Tests</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Schizophrenia</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Weight Gain - drug effects</subject><subject>Young Adult</subject><issn>0165-1781</issn><issn>1872-7123</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFks9u1DAQxiMEokvhFSpfEKcsHiexnQsCVeWPVIkDcLa8zkTrbTYOHm9RHoJ3xunuUokLJ1v2b76xv2-K4gr4GjjIt7v1RLPbRqS14MshrDmoJ8UKtBKlAlE9LVYZbEpQGi6KF0Q7zrmAtn1eXAgAqVvBV8XvGxuHmWWdKYyELAVmx-QfxEPyjqUtRjvNzBKzzA1-9M4ObG_jHUYWekaHDeHPA47pUcSPSxlLEW3aLzeZm2zyeUvsl09b1vtIqcTJU-iQHbuRp5fFs94OhK9O62Xx4-PN9-vP5e3XT1-uP9yWrm5EKl0rne21dNK2kotKSnC1VbaqhWvaqpWN1thXVaMs1NyKrulVJzsnhdw0SvHqsnhz1J1iyG-nZPaeHA6DHTEcyGjJQWsNVSblkXQxEEXszRR9_v1sgJslCbMz5yTMkoQBMDmJXHh1anHY7LH7W3a2PgOvT4ClbGkf7eg8PXI1b5v6Qej9kcNsyL3HaMhlJx12PqJLpgv-_29594_EOcg7nJF24RDHbLcBQ8Jw822Zm2VsIE-M4q2o_gCpscJs</recordid><startdate>20110515</startdate><enddate>20110515</enddate><creator>Stauffer, Virginia L</creator><creator>Case, Michael</creator><creator>Kinon, Bruce J</creator><creator>Conley, Robert</creator><creator>Ascher-Svanum, Haya</creator><creator>Kollack-Walker, Sara</creator><creator>Kane, John</creator><creator>McEvoy, Joseph</creator><creator>Lieberman, Jeffrey</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110515</creationdate><title>Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis</title><author>Stauffer, Virginia L ; Case, Michael ; Kinon, Bruce J ; Conley, Robert ; Ascher-Svanum, Haya ; Kollack-Walker, Sara ; Kane, John ; McEvoy, Joseph ; Lieberman, Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Basal Ganglia Diseases - chemically induced</topic><topic>Benzodiazepines - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Haloperidol</topic><topic>Haloperidol - therapeutic use</topic><topic>Humans</topic><topic>International Cooperation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental Disorders - drug therapy</topic><topic>Mental Disorders - physiopathology</topic><topic>Neuropharmacology</topic><topic>Olanzapine</topic><topic>Pharmacology. Drug treatments</topic><topic>Prediction models</topic><topic>Predictive Value of Tests</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Schizophrenia</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Weight Gain - drug effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stauffer, Virginia L</creatorcontrib><creatorcontrib>Case, Michael</creatorcontrib><creatorcontrib>Kinon, Bruce J</creatorcontrib><creatorcontrib>Conley, Robert</creatorcontrib><creatorcontrib>Ascher-Svanum, Haya</creatorcontrib><creatorcontrib>Kollack-Walker, Sara</creatorcontrib><creatorcontrib>Kane, John</creatorcontrib><creatorcontrib>McEvoy, Joseph</creatorcontrib><creatorcontrib>Lieberman, Jeffrey</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatry research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stauffer, Virginia L</au><au>Case, Michael</au><au>Kinon, Bruce J</au><au>Conley, Robert</au><au>Ascher-Svanum, Haya</au><au>Kollack-Walker, Sara</au><au>Kane, John</au><au>McEvoy, Joseph</au><au>Lieberman, Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis</atitle><jtitle>Psychiatry research</jtitle><addtitle>Psychiatry Res</addtitle><date>2011-05-15</date><risdate>2011</risdate><volume>187</volume><issue>1</issue><spage>42</spage><epage>48</epage><pages>42-48</pages><issn>0165-1781</issn><eissn>1872-7123</eissn><coden>PSRSDR</coden><abstract>Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-driven threshold for early response of ≥ 26.2% improvement from baseline on the Positive and Negative Syndrome Scale (PANSS0–6 ) Total score to determine whether response at Week 2 of treatment may predict response at Week 12 in a randomized, double-blind trial of olanzapine versus haloperidol for treatment of patients with first-episode psychosis ( N = 225). Later response was defined as a ≥ 40% and ≥ 50% improvement in PANSS Total0–6 score and as remission. At Week 2, 43% (97/225) of patients were identified as early responders. At a threshold for later response of ≥ 50% improvement in PANSS0–6 Total score, early non-response most strongly predicted later non-response, demonstrating high specificity (74%) and high negative predictive value (80%). As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis.</abstract><cop>Kidlington</cop><pub>Elsevier Ireland Ltd</pub><pmid>21168920</pmid><doi>10.1016/j.psychres.2010.11.017</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-1781 |
ispartof | Psychiatry research, 2011-05, Vol.187 (1), p.42-48 |
issn | 0165-1781 1872-7123 |
language | eng |
recordid | cdi_proquest_miscellaneous_860188813 |
source | Elsevier |
subjects | Adolescent Adult Adult and adolescent clinical studies Antipsychotic Agents - therapeutic use Basal Ganglia Diseases - chemically induced Benzodiazepines - therapeutic use Biological and medical sciences Double-Blind Method Female Follow-Up Studies Haloperidol Haloperidol - therapeutic use Humans International Cooperation Male Medical sciences Mental Disorders - drug therapy Mental Disorders - physiopathology Neuropharmacology Olanzapine Pharmacology. Drug treatments Prediction models Predictive Value of Tests Psychiatric Status Rating Scales Psychiatry Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Schizophrenia Time Factors Treatment Outcome Weight Gain - drug effects Young Adult |
title | Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A14%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20response%20to%20antipsychotic%20therapy%20as%20a%20clinical%20marker%20of%20subsequent%20response%20in%20the%20treatment%20of%20patients%20with%20first-episode%20psychosis&rft.jtitle=Psychiatry%20research&rft.au=Stauffer,%20Virginia%20L&rft.date=2011-05-15&rft.volume=187&rft.issue=1&rft.spage=42&rft.epage=48&rft.pages=42-48&rft.issn=0165-1781&rft.eissn=1872-7123&rft.coden=PSRSDR&rft_id=info:doi/10.1016/j.psychres.2010.11.017&rft_dat=%3Cproquest_cross%3E860188813%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=860188813&rft_id=info:pmid/21168920&rfr_iscdi=true |